Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.

@article{Costa2006ImprovementOT,
  title={Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.},
  author={Daniel Botelho Costa and Mark S. Huberman},
  journal={Diabetes care},
  year={2006},
  volume={29 7},
  pages={1711}
}
on a scale from 0 (worst) to 5 (best). Overall, 9% of patients rated the pen as 5, 38.4% as 4, 26.4% as 3, 11.7% as 2, 8.8% as 1, and 2.9% as 0. A significant amount (61.7%) of subjects exchanged their OptiPen Pro-1 for an insulin syringe or insulin detemir. In the U.K., the MHRA has issued an alert about possible problems with the OptiPen Pro-1. Possible… CONTINUE READING